Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
暂无分享,去创建一个
Michael Lock | Stewart Gaede | Suresh Senan | Belal Ahmad | Glenn S Bauman | David A Palma | Alexander V Louie | Robert Olson | Anand Swaminath | Cornelis Haasbeek | Mitchell Liu | Devin Schellenberg | B. Yaremko | M. Lock | S. Senan | G. Bauman | A. Louie | G. Rodrigues | D. Palma | B. Ahmad | S. Gaede | Mitchell C C Liu | C. Haasbeek | A. Warner | R. Olson | N. Kopek | Sashendra Senthi | Andrew Warner | George B Rodrigues | Brian P Yaremko | A. Swaminath | S. Harrow | L. Mulroy | D. Schellenberg | G. Griffioen | S. Senthi | K. Moore | S. Currie | Neil Kopek | Stephen Harrow | Liam Mulroy | Gwendolyn Griffioen | Karen Moore | Suzanne Currie
[1] G. Rodrigues,et al. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature. , 2013, Lung cancer.
[2] Maria Werner-Wasik,et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial , 2004, The Lancet.
[3] P. Iyengar,et al. Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial , 2018, JAMA oncology.
[4] Steven E. Schild,et al. Non-small cell lung cancer, version 5.2017: Clinical practice guidelines in oncology , 2017 .
[5] T. Treasure,et al. Pulmonary metastasectomy in colorectal cancer: a systematic review and quantitative synthesis , 2010, Journal of the Royal Society of Medicine.
[6] T. Treasure,et al. Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial , 2017 .
[8] M. Ridder,et al. Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] Manish R. Sharma,et al. Randomized phase II trials: a long-term investment with promising returns. , 2011, Journal of the National Cancer Institute.
[10] Y Maruyama,et al. A randomized trial of surgery in the treatment of single metastases to the brain. , 1990, The New England journal of medicine.
[11] J. Barney,et al. Adenocarcinoma of the Kidney with Metastasis to the Lung: Cured by Nephrectomy and Lobectomy1 , 1939 .
[12] M. Roach,et al. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. , 2015, European urology.
[13] F. Macbeth. Avoid Futile Therapy. , 2017, International journal of radiation oncology, biology, physics.
[14] Henry Knipe,et al. Oligometastases , 2016, Radiopaedia.org.
[15] L. Fallowfield,et al. Pulmonary metastasectomy in colorectal cancer: time for a trial. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[16] L. Fallowfield,et al. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] D. Palma,et al. Definitive Stereotactic Body Radiotherapy (SBRT) for Extracranial Oligometastases: An International Survey of >1000 Radiation Oncologists , 2017, American journal of clinical oncology.
[18] E. Guerra,et al. Use of stereotactic body radiation therapy for oligometastatic recurrent prostate cancer: A systematic review , 2018, Journal of medical imaging and radiation oncology.
[19] Julian C. Hong,et al. Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis , 2018, PloS one.
[20] V. Prasad,et al. Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology , 2018, JAMA oncology.
[21] E. Goetghebeur,et al. Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] R. Timmerman,et al. Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] David A. Palma,et al. The oligometastatic state—separating truth from wishful thinking , 2014, Nature Reviews Clinical Oncology.
[24] Boris Freidlin,et al. Design issues of randomized phase II trials and a proposal for phase II screening trials. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] D. Fraker,et al. The rise in metastasectomy across cancer types over the past decade , 2015, Cancer.
[26] L. Banfield,et al. Ablative Therapies in Metastatic Breast Cancer: A Systematic Review , 2017, Breast Cancer Research and Treatment.
[27] J. Lee,et al. Local Consolidative Therapy versus Maintenance Therapy/Observation for Patients with Oligometastatic Non-Small Cell Lung Cancer without Progression after Front-Line Systemic Therapy: Results of a Multi-Institutional Phase II Randomized Study , 2016, The Lancet. Oncology.
[28] Joe Y. Chang,et al. Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? , 2016, Nature Reviews Clinical Oncology.
[29] B. Yaremko,et al. Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): Study protocol for a randomized phase II trial , 2012, BMC Cancer.